BiotechTube

Forteo

Pre-clinicalUNKNOWN
1 views this week 0 watching💤 Quiet
Interest: 22/100
22
Hype Score

Development Stage

1
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Osteoporosis

Conditions

Osteoporosis

Trial Timeline

Jun 1, 2008 → Jan 1, 2025

NCT ID
NCT01155245

About Forteo

Forteo is a pre-clinical stage product being developed by Eli Lilly for Osteoporosis. The current trial status is unknown. This product is registered under clinical trial identifier NCT01155245. Target conditions include Osteoporosis.

What happened to similar drugs?

20 of 20 similar drugs in Osteoporosis were approved

Approved (20) Terminated (0) Active (0)
✅raloxifene + PlaceboEli LillyApproved
✅raloxifene + placeboEli LillyApproved
✅MENATETRANONEEisaiApproved
✅Menatetrenone (Vitamin K2)EisaiApproved
✅teriparatideEli LillyApproved
✅Teriparatide + Aspara-CA 600 mg + Alfarol 1.0 µgEli LillyApproved
✅Teriparatide + Strontium ranelateEli LillyApproved

Hype Score Breakdown

Clinical
3
Activity
4
Company
15
Novelty
0
Community
0

Clinical Trials (2)

NCT IDPhaseStatus
NCT01155245Pre-clinicalUNKNOWN
NCT01078805Pre-clinicalCompleted

Competing Products

20 competing products in Osteoporosis

See all competitors
ProductCompanyStageHype Score
ENZ215 + ProliaAlkem LaboratoriesPhase 3
40
Teriparatide + Alendronate Sodium + Placebo + PlaceboEli LillyPhase 3
40
TeriparatideEli LillyPhase 3
40
teriparatide + teriparatide + Placebo + Calcium Supplement + Vitamin D SupplementEli LillyPhase 3
40
raloxifene + PlaceboEli LillyApproved
43
Subcutaneous Teriparatide + Transdermal TeriparatideEli LillyPhase 2
35
teriparatide 20 micrograms/day subcutaneous + calcitonin 100 IU/day subcutaneousEli LillyPhase 3
40
raloxifene + placeboEli LillyApproved
43
Teriparatide + Salmon CalcitoninEli LillyPhase 3
40
arzoxifene + PlaceboEli LillyPhase 2
35
teriparatide 20 micrograms/day subcutaneous + salmon calcitonin 100 IU/day subcutaneousEli LillyPhase 3
40
CT-P41 + US-licensed ProliaCelltrionPhase 3
40
ED-71 + Alfacalcidol + ED-71 placebo + Alfacalcidol placeboChugai PharmaceuticalPhase 3
40
Eldecalcitol soft capsulesChugai PharmaceuticalPre-clinical
22
ibandronic acid 0.5mg + RIS placebo + 1.0mg ibandronic acid + ibandronic acid placebo + 2.5mg RISChugai PharmaceuticalPhase 3
40
Denosumab + Placebo + Alendronate sodium hydrateDaiichi SankyoPhase 3
40
YM529 / ONO-5920Astellas PharmaPhase 2/3
38
ONO-5920Astellas PharmaPhase 3
40
Minodronic acid hydrateAstellas PharmaPhase 3
40
ONO-5920 / YM529Astellas PharmaPhase 1
29